blacktop

- Advertisement -

Eularis to Address Making the Right Research Decision for ROI at 3rd Annual Pharmaceutical Market Research Summit

The Link Between Research and Decisions on Bottom Line Return at 3rd Annual Pharmaceutical Market Research Summit

NEW YORK, N.Y. and LONDON, U.K. — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return. At 11:45 a.m. on Tuesday 29 April 2008, Dr. Bates will deliver a presentation titled, “How to Tell if You Are Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return.”

Bates will challenge the conference attendees and will expose where both traditional market research and ROI can go wrong when used to guide marketing decisions return. She will also provide attendees with ideas on how to utilize market research data to provide input into ROI measurement for their marketing teams.

Andree BatesBates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis.

The 3rd Annual Pharmaceutical Market Research Summit takes place in Philadelphia. The summit program features detailed case studies from some of the industry’s most prominent organizations and provides information needed to improve market research initiatives.

WHO: Eularis

WHAT: Presentation on Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return

WHEN: 29 April 2008 at 11:45 a.m. EDT

WHERE: 3rd Annual Pharmaceutical Market Research Summit
Hyatt Regency at Penn’s Landing, Philadelphia

Under Bates’ leadership, Eularis issued three related research reports in the past year, including:

“Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line” (http://www.pharmamarketingroi.com/),

“Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?” (http://www.pharmaindustrysfe.com/), and

“Ensuring Profitable Patient Adherence Programs by Effectively Using Analytics to Release the Hidden Value Available to the Bottom Line from Adherence” (http://www.patientadherenceroi.com/).

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance.

Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

All trademarks acknowledged.

National News Desk
 
Comments are closed.